| 1.24 -0.02 (-1.59%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.61  |
1-year : | 1.79 |
| Resists | First : | 1.38 |
Second : | 1.53 |
| Pivot price | 1.27  |
|||
| Supports | First : | 1.12 |
Second : | 0.94 |
| MAs | MA(5) : | 1.22 |
MA(20) : | 1.3 |
| MA(100) : | 1.58 |
MA(250) : | 1.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 20.8 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 6.61 | Low : | 0.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OTLK ] has closed above bottom band by 35.3%. Bollinger Bands are 72% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.28 |
| Low: | 1.2 - 1.21 | 1.21 - 1.22 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Mon, 03 Nov 2025
Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 to FDA for Wet AMD Treatment - Quiver Quantitative
Mon, 03 Nov 2025
Outlook Therapeutics (Nasdaq: OTLK) re-submits BLA for LYTENAVA in wet AMD - Stock Titan
Wed, 29 Oct 2025
Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59 - Nasdaq
Tue, 30 Sep 2025
HC Wainwright & Co. Reiterates Outlook Therapeutics (OTLK) Neutral Recommendation - Nasdaq
Mon, 29 Sep 2025
Outlook Therapeutics Stock: To Buy or Not? - StocksToTrade
Tue, 02 Sep 2025
Outlook Therapeutics Requests Type A Meeting with FDA - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 2.825e+007 (%) |
| Held by Institutions | 36.3 (%) |
| Shares Short | 5,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.251e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 46.2 % |
| Return on Equity (ttm) | -130.7 % |
| Qtrly Rev. Growth | 1.51e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.08246e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.83 |
| Dividend | 0 |
| Forward Dividend | 2.17e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|